Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Cytokinetics, Incorporated (CYTK)

47.25   -0.22 (-0.46%) 06-26 21:53
Open: 47.98 Pre. Close: 47.47
High: 48.0999 Low: 45.2544
Volume: 1,366,985 Market Cap: 4,047(M)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 48.21 - 48.45 48.45 - 48.64
Low: 44.62 - 44.93 44.93 - 45.19
Close: 46.8 - 47.29 47.29 - 47.68

Technical analysis

as of: 2022-06-24 4:39:09 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 56.18     One year: 65.61
Support: Support1: 41.54    Support2: 37.5
Resistance: Resistance1: 48.09    Resistance2: 56.18
Pivot: 41.47
Moving Average: MA(5): 44.26     MA(20): 41.42
MA(100): 38.45     MA(250): 35.88
MACD: MACD(12,26): 1.3     Signal(9): 0.6
Stochastic oscillator: %K(14,3): 89     %D(3): 80
RSI: RSI(14): 66.7
52-week: High: 48.09  Low: 17.71
Average Vol(K): 3-Month: 886 (K)  10-Days: 1,035 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CYTK ] has closed Bollinger Bands are 33.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 24 Jun 2022
Should Biotechnology Stock Cytokinetics, Inc. (CYTK) Be in Your Portfolio Friday? - InvestorsObserver

Fri, 24 Jun 2022
Cytokinetics announces upcoming AdCom meeting on heart failure therapy (NASDAQ:CYTK) - Seeking Alpha

Thu, 16 Jun 2022
2022-06-16 | NDAQ:CYTK | Press Release | Cytokinetics Incorporated - Stockhouse

Mon, 13 Jun 2022
Cytokinetics (NASDAQ:CYTK) Trading Up 1.2% - Defense World

Thu, 09 Jun 2022
Cytokinetics (NASDAQ:CYTK) Given New $72.00 Price Target at Piper Sandler - MarketBeat

Thu, 09 Jun 2022
Analysts Expect Cytokinetics, Incorporated (NASDAQ:CYTK) to Post -$1.04 Earnings Per Share - Defense World

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 84 (M)
Shares Float 84 (M)
% Held by Insiders 4.8 (%)
% Held by Institutions 114.1 (%)
Shares Short 8,010 (K)
Shares Short P.Month 7,500 (K)

Stock Financials

EPS -3.11
EPS Est Next Qtl -0.39
EPS Est This Year -2.5
EPS Est Next Year -2.47
Book Value (p.s.) 2.97
Profit Margin (%) 0
Operating Margin (%) -264.6
Return on Assets (ttm) -17
Return on Equity (ttm) -120.6
Qtrly Rev. Growth 727
Gross Profit (p.s.) -1.07
Sales Per Share 0.83
EBITDA (p.s.) -2.19
Qtrly Earnings Growth 0
Operating Cash Flow -143 (M)
Levered Free Cash Flow -180 (M)

Stock Valuations

PE Ratio -15.2
PEG Ratio -0.6
Price to Book value 15.9
Price to Sales 56.61
Price to Cash Flow -27.98

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.